Hubei Bio registers fifth KIF18A inhibitor trial to enter the clinic
HW221043 becomes the fifth KIF18A inhibitor to reach human testing, joining Volastra and Accent Therapeutics programs in a target still without a single completed trial.
Executive Summary
- Hubei Bio-Pharmaceutical Industrial Technological Institute has registered a Phase 1 dose-escalation and expansion study of its oral KIF18A inhibitor in patients with advanced tumors who have exhausted standard therapy.
- The mechanism now has five clinical-stage entrants across US and Chinese sponsors, none of which has produced a completed trial, giving the field a target that is being chased in parallel by multiple companies without a validated result yet in hand.
- The trial is open-label and single-arm, structured to establish a tolerable dose and early antitumor activity rather than to support approval on its own, consistent with how the other KIF18A programs in this class have been designed.
- The entry adds density to a still-unproven mechanism class and gives investors another data point on how many companies believe KIF18A inhibition is worth pursuing before any peer has shown it works in humans.
The registration
The study, listed under NCT07719920, will test HW221043 in adults with recurrent or metastatic tumors who have failed, are ineligible for, or lack access to standard therapy. It is set to begin dosing on July 30, 2026, and the sponsor targets 99 patients across dose-escalation and expansion cohorts, with a primary completion date of June 30, 2029. The trial is open-label, single-arm, and run out of sites in China. NCT07719920A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid TumorsNCT07719920
How it will be judged
The registered primary endpoints are adverse-event and serious-adverse-event incidence and dose-limiting toxicity, tracked over two years, the standard measures for a first-in-human dose-finding study. Secondary measures include pharmacokinetic parameters such as Cmax, Tmax, and AUC, along with objective response rate and progression-free survival collected over two to three years. That structure means the trial is built to establish a tolerable dose and early hints of activity, not to support approval on its own; the study is not designated registrational. NCT07719920A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid TumorsNCT07719920
The KIF18A field
HW221043 enters a mechanism class where four other KIF18A inhibitors are already in clinical testing. Volastra Therapeutics' VLS-1488 is being tested in a Phase 1/2 trial in high-grade serous ovarian cancer, and the same sponsor's sovilnesib is in Phase 1 testing in ovarian and breast cancer. Accent Therapeutics' ATX-295 and Zhejiang Hisun Pharmaceutical's HS387 are both in Phase 1 tumor trials. None of these programs has a completed trial on record, and no KIF18A inhibitor has reached Phase 3 or an approval; the class remains in early human testing across every sponsor pursuing it. NCT05902988+1NCT05902988NCT06799065
Where HW221043 differs
HW221043 is dosed orally as a tablet, the same modality class as its peers, and it is being tested as a monotherapy rather than in combination. Its trial excludes patients with any prior exposure to a KIF18A inhibitor, meaning the study is designed to capture a treatment-naive population for this mechanism rather than a post-progression salvage setting. Beyond dosing format, the registered protocol does not distinguish HW221043's design from the other Phase 1 KIF18A programs already recruiting. NCT07719920A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid TumorsNCT07719920
The broader field
KIF18A field activity has held flat, with 18 trials in the recent period against 18 in the prior period, indicating the mechanism has neither accelerated nor lost momentum going into this trial's registration. Advanced-tumor trials overall skew toward Phase 1, with five of eight comparable industry trials in the indication still in that earliest stage, underscoring how much of the surrounding activity, KIF18A included, remains in dose-finding rather than efficacy-confirming work.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.